Potential therapeutic role of histatin derivative P-113D in experimental rat models of Pseudomonas aeruginosa sepsis

Journal of Infectious Diseases

Volumn 190, Issue 2, 2004, Pages 356-364

  Cirioni, Oscar ^a   Giacometti, Andrea ^a,d   Ghiselli, Roberto ^a   Orlando, Fiorenza ^b   Kamysz, Wojciech ^c   D'Amato, Giuseppina ^a   Mocchegiani, Federico ^a   Lukasiak, Jerzy ^c   Silvestri, Carmela ^a   Saba, Vittorio ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d c/o Ospedale Regionale ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIUM LIPOPOLYSACCHARIDE; DEXTRO ALANYLLYSYLARGINYLHISTIDYLHISTIDYLGLYCYLTYROSYLLYSYLARGINYLLYSYLPHENYLALANYL HISTIDINAMIDE; ENDOTOXIN; HISTATIN; IMIPENEM; PEPTIDE; POLYMYXIN B; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; EXPERIMENTAL MODEL; IN VITRO STUDY; LETHALITY; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SEPSIS;

ABDOMINAL CAVITY; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; ENDOTOXINS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; PLASMA; POLYMYXINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR; SALIVARY PROTEINS; SEPSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3242741684     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421913     Document Type: Article

References (40)

1. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999; 29:595-607.
2. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27: 1421-8.
3. Martino R, Santamaria A, Munoz L, et al. Bacteremia by gram-negative bacilli in patients with hematologic malignancies: comparison of the clinical presentation and outcome of infections by enterobacteria and non-glucose-fermenting gram-negative bacilli. Acta Haematol 1999; 102:7-11.
4. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factor influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10:629-35.
5. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-64.
6. Forkner CE Jr, Frei E 3rd, Edgcomb JH, Utz JP. Pseudomonas septicemia: observations on twenty-three cases. Am J Med 1958; 25:877-89.
7. Bone RC. Pathophysiology of sepsis. Ann Intern Med 1991; 115:457-69.
8. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338:732-6.
9. Hardaway RM. A review of septic shock. Am Surg 2000; 66:22-9.
10. Iwagaki A, Porro M, Pollack M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun 2000; 68:1655-63.
11. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNFα promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282:561-8.
12. Bone RC. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993; 6:57-68.
13. Ruiz-Perez B, Cisneros RL, Matsumoto T, et al. Protection against lethal intra-abdominal sepsis by 1-(3-dimethylaminopropyl)-3-ethylurea. J Infect Dis 2003; 188:378-87.
14. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
15. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-8.
16. Klastersky J. Empirical treatment of sepsis in neutropenic patients. Int J Antimicrob Agents 2000; 16:131-3.
17. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Antimicrob Chemother 1993; 31:919-26.
18. Prins JM, Kuijper EJ, Mevissen MLCM, Speelman P, van Deventer SJH. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63:2236-42.
19. Byl B, Clevenbergh P, Kentos A, et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 2001; 20:804-7.
20. Giacometti A, Cirioni O, Greganti G, Quarta M, Scalise G. In vitro activity of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Antimicrob Agents Chemother 1998; 42:3320-4.
21. Giacometti A, Cirioni O, Ghiselli R, et al. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med 2001; 29:1666-9.
22. Giacometti A, Cirioni O, Ghiselli R, et al. Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. Gut 2003; 52:874-8.
23. Levy O. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood 2000; 96:2664-72.
24. Hancock REW. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1:156-64.
25. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43:1317-23.
26. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 2000; 97:8856-61.
27. Gough M, Hancock REW, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64:4922-7.
28. Oppenheim FG, Xu T, McMillian FM, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion: isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263:7472-7.
29. Tsai H, Bobek LA. Human salivary histatins: promising antifungal therapeutic agents. Crit Rev Oral Biol Med 1998; 9:480-97.
30. Sajjan US, Tran LT, Sople N, et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 2001; 45:3437-44.
31. Rothstein DM, Spacciapoli P, Tran LT, et al. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother 2001; 45:1367-73.
32. Sugiyama K. Anti-lipopolysaccharide activity of histatins, peptides from human saliva. Experientia 1993; 49:1095-7.
33. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990; 35: 161-214.
34. Christensen T. Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem Scand Ser B (Organic Chem Biochem) 1979; 33:763-6.
35. Kamysz W, Kochanska B, Kedzia A, Ochocinska J, Mackiewicz Z, Kupryszewski G. Statherin SV2 and its analogues: synthesis and evaluation of antimicrobial activity. Polish J Chem 2002; 76:801-6.
36. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard, M7-A5. Wayne, PA: NCCLS, 2001.
37. Lamping N, Dettmer R, Schröder NWJ, Pfeil D, Hallatscheck D, Burger R. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998; 101:2065-71.
38. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg 2001; 88:22-30.
39. Drabick JJ, Bhattacharjee AK, Hoover DL, et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob Agents Chemother 1998; 42:583-8.
40. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.